Clinical Trials · NCT06149260
Subcutaneous Semaglutide in Systemic Scleroderma
- Phase
- Phase 1
- Recruitment status
- Unknown
- Sponsor
- Second Xiangya Hospital of Central South University
- Enrollment
- 10
- Start date
- Feb 2024
- Locations
- 1 site, China
- Primary endpoint
- Change in modified Rodnan skin score (mRSS) at week 24